EN DE
Watch Suzhou Novoprotein Scientific Co. Ltd. A for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Suzhou Novoprotein Scientific Co. Ltd. A (688137) fair value: what the stock is really worth

As of Oct 22, 2026: fair value (intrinsic value) of Suzhou Novoprotein Scientific Co. Ltd. A stock ¥24.86, price ¥107, upside -76.7%, quality 46 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · CN · ISIN CNE100005NZ4

SN Suzhou Novoprotein Scientific Co. Ltd. A logo Thin data Oct 4, 2026

Suzhou Novoprotein Scientific Co. Ltd. A

688137 · SHG

Weakest SetupStrongly overvalued and low quality.

Our calculation puts a fair price 77% below what the stock costs today.

Quality 46/100
Mixed vs. peers (4/10)
Fair value ¥24.86 · Strongly overvalued (−76.7%)
Weak Growth (revenue 5y −4.0 %/yr in CNY)
Loss-making · -54.2% net margin (TTM)
Negative free cash flow
Narrow moat 10/100 · thin data
Thin data
Watch Suzhou Novoprotein Scientific Co. Ltd. A for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥161.18 ¥28.94 Fair Value ¥24.86 Sep 2022 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 4, 2026.

How to read this chart

49‑month range ¥28.94 – ¥161.18 · fair‑value band ¥16.41 – ¥31.07 · the ¥106.80 price screens above the ¥24.86 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 4, 2026.

Follow Suzhou Novoprotein Scientific Co. Ltd. A in your weekly email

Every Wednesday you see whether Suzhou Novoprotein Scientific Co. Ltd. A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Novoprotein Scientific Inc. researches, develops, produces, and sells raw materials and technical solutions for bio-pharmaceutical enterprises and research institutions in Asia, Europe, the United States, and Oceania.

Show moreShow less

It offers cytokines, target proteins, mRNA vaccine and drug enzymes, recombinant antibodies, enzymes and reagents, biosimilar reference antibodies, gene and cell therapy, molecular research and diagnosis, and virus-related products, including antigens, antibodies and test kits.

The company also provides protein expression and purification; industrial strain and process development; antibody development and production service; antibody screening and optimization services; and IVT mRNA/circRNA /SaRNA production services.

It offers its products and services in the fields of biopharmaceuticals, mRNA vaccines and drugs, in vitro diagnostics, biological drugs, basic research of life sciences, and other areas. The company was founded in 2009 and is headquartered in Suzhou, China.

Stock analysis

Suzhou Novoprotein Scientific Co. Ltd. A (688137) currently trades at ¥106.80, while our model-based Fair Value estimate is ¥24.86, 76.7% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of ¥24.86 per share, and 0 of the 3 models we run sit above the ¥106.80 price.

Bear case: the Dividend Discount group reads lowest at ¥3.49, and 3 of the 3 models stay below the price. Data coverage for this calculation is low.

Scenario range: ¥16.41 (bear) to ¥31.07 (bull), the price of ¥106.80 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Suzhou Novoprotein Scientific Co. Ltd. A reported revenue of 146M CNY in FY2025 versus 342M CNY in FY2021, a compound −19.1%/yr. Reported net income was −77.8M CNY in FY2025.

Key figures

Market cap 7.5B CNY (≈ $1.1B) Small · P/S ratio 73.4 · EPS (TTM) ¥−1.19 · Dividend yield 0.3% · Net margin −54.2% · Return on equity −4.1% · Return on assets (EBIT) 7.4% · Operating margin −66.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 34% below its 52-week high and 217% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 2% fair-value upside, at −77%, 688137 screens richer than that median.

Fair Value models

Bear ¥16.41 Fair Value ¥24.86 Bull ¥31.07
Price ¥106.80 · Upside -76.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Gordon GGM ¥3.28 ¥3.49 ¥3.80 69
DDM Multi-Stage ¥3.28 ¥3.74 ¥4.31 67
NCAV (Graham) ¥16.41 ¥24.86 ¥31.07 52
All 3 models by family
Dividend Discount
Gordon GGM ¥3.28 ¥3.49 ¥3.80 69
DDM Multi-Stage ¥3.28 ¥3.74 ¥4.31 67
Asset-Based
NCAV (Graham) ¥16.41 ¥24.86 ¥31.07 52

Open the full fair value analysis →

Quality Score breakdown

Overall quality 46/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 4
How much profit the company makes from its sales and capital
Quality Growth 51
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 11
How calm the share price moves, does not count
Momentum 100
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 79
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+14.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−17.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.0%
Start year 2020 (pandemic)
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
57.7% (2020) → −45.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

688137 screens overvalued: fair value 77% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Suzhou Novoprotein Scientific Co. Ltd. A with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 598 stocks

Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 46 · Above median
Fair Value upside −76.7% · Bottom 25%
Profitability
Return on assets −3.6% · Above median
Net margin (12 months) −54.2% · Bottom 25%
Operating margin (12 months) −66.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 6.7% · Above median
Dividend yield (12 months) 0.3% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 3.67× · Priciest 25%
P/S (12 months) 48.86× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)34 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)6 · sector 23

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $805.67 $1,275 +58% vs 688137
Vertex Pharmaceuticals Incorporated VRTX $514.65 $566.12 +10% vs 688137
Samsung Biologics Co 207940 1,417,000 KRW 1,558,700 KRW +10% vs 688137
WuXi Biologics (Cayman) Inc 2269 HK$49.40 HK$54.34 +10% vs 688137
argenx SE ARGX $890.05 $908.40 +2% vs 688137
Alnylam Pharmaceuticals, Inc ALNY $225.10 $217.88 −3% vs 688137
CSL Limited CSL A$196.08 A$178.71 −9% vs 688137
BeOne Medicines AG ONC $386.46 $254.12 −34% vs 688137
Celltrion, Inc 068270 197,600 KRW 74,944 KRW −62% vs 688137
Royalty Pharma plc RPRX $62.15 $19.01 −69% vs 688137

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Suzhou Novoprotein Scientific Co. Ltd. A · Fair Value
¥24.86 −77%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Suzhou Novoprotein Scientific Co. Ltd. A Fair Value". https://www.fairvalue-calculator.com/stock/688137

Frequently asked questions

Is Suzhou Novoprotein Scientific Co. Ltd. A (688137) overvalued or undervalued?
As of Oct 4, 2026, our model estimates a fair value of ¥24.86 versus a price of ¥106.80, about −77% upside (overvalued).
What is the fair value of 688137?
Our model-based fair value for Suzhou Novoprotein Scientific Co. Ltd. A is ¥24.86 (as of Oct 4, 2026), built from audited fundamentals. The current price: ¥106.80.
What is the quality score of 688137?
Suzhou Novoprotein Scientific Co. Ltd. A has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Suzhou Novoprotein Scientific Co. Ltd. A (688137)?
Our model-based price target is the fair value of ¥24.86 (as of Oct 4, 2026) from 3 valuation models. Cautious scenario ¥16.41, optimistic scenario ¥31.07. It is a calculation from audited fundamentals, not an analyst target.
What is the Suzhou Novoprotein Scientific Co. Ltd. A stock forecast for 2026?
Our models put fair value at ¥24.86, about −77% upside versus a price of ¥106.80 (overvalued). Cautious scenario ¥16.41, optimistic scenario ¥31.07. The calculation is refreshed regularly with new filings.
What is the revenue of Suzhou Novoprotein Scientific Co. Ltd. A (688137)?
Suzhou Novoprotein Scientific Co. Ltd. A reported trailing-twelve-month revenue of about 153M CNY (latest available figure, as of Oct 4, 2026).
Does Suzhou Novoprotein Scientific Co. Ltd. A pay a dividend?
Suzhou Novoprotein Scientific Co. Ltd. A currently shows a dividend yield of 0.31% relative to its recent price (as of Oct 4, 2026).
What is the intrinsic value of Suzhou Novoprotein Scientific Co. Ltd. A (688137)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Suzhou Novoprotein Scientific Co. Ltd. A it is ¥24.86 per share (as of Oct 4, 2026), against a price of ¥106.80. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is Suzhou Novoprotein Scientific Co. Ltd. A stock overvalued or undervalued in 2026?
As of Oct 4, 2026, 688137 trades above its calculated fair value: price ¥106.80, fair value ¥24.86, a gap of about −77% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688137?
No. The price is what the market pays today (¥106.80); the fair value is what the company's own numbers justify (¥24.86). For Suzhou Novoprotein Scientific Co. Ltd. A the two are ¥81.94 per share apart. That gap is exactly why we show both numbers side by side.
How much is Suzhou Novoprotein Scientific Co. Ltd. A worth?
The market values Suzhou Novoprotein Scientific Co. Ltd. A at about 7.5B CNY (market capitalisation, as of Oct 4, 2026). Per share that is ¥106.80; our models calculate a fair value of ¥24.86 per share.
What do the bullish and bearish scenarios say about 688137?
Our models span a range for Suzhou Novoprotein Scientific Co. Ltd. A: cautious scenario ¥16.41, base ¥24.86, optimistic ¥31.07 per share (as of Oct 4, 2026, price ¥106.80). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Suzhou Novoprotein Scientific Co. Ltd. A (688137)?
Balance-sheet figures for Suzhou Novoprotein Scientific Co. Ltd. A (as of Oct 4, 2026): return on equity −4.1%. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is 688137 from its 52-week high?
Suzhou Novoprotein Scientific Co. Ltd. A trades at ¥106.80, about 34% below its 52-week high of ¥161.18 and 217% above the low of ¥33.67 (as of Oct 22, 2026). Distance from the high says nothing about value: that is what the fair value of ¥24.86 is for.
Which stocks are comparable to Suzhou Novoprotein Scientific Co. Ltd. A?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Suzhou Novoprotein Scientific Co. Ltd. A stock attractive at the current price?
The data as of Oct 4, 2026: price ¥106.80, calculated fair value ¥24.86 (−77%), Quality Score 46/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688137 calculated?
We run Suzhou Novoprotein Scientific Co. Ltd. A through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥24.86, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Suzhou Novoprotein Scientific Co. Ltd. A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Suzhou Novoprotein Scientific Co. Ltd. A (688137)?
The closing price on Oct 22, 2026 was ¥106.80. Our model-based fair value is ¥24.86, about −77% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Suzhou Novoprotein Scientific Co. Ltd. A right now?
The price sits above even our optimistic bull case (¥31.07). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (46/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (¥16.41 to ¥31.07) leaves room in how you read the outcome.

Key figures of Suzhou Novoprotein Scientific Co. Ltd. A

How large is the market capitalisation of Suzhou Novoprotein Scientific Co. Ltd. A (688137)?
The market capitalisation of Suzhou Novoprotein Scientific Co. Ltd. A is 7.5B CNY (≈ $1.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Suzhou Novoprotein Scientific Co. Ltd. A (688137)?
The price-to-sales ratio of Suzhou Novoprotein Scientific Co. Ltd. A is 73.4 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Suzhou Novoprotein Scientific Co. Ltd. A (688137)?
Earnings per share at Suzhou Novoprotein Scientific Co. Ltd. A are ¥−1.19. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Suzhou Novoprotein Scientific Co. Ltd. A (688137)?
The dividend yield of Suzhou Novoprotein Scientific Co. Ltd. A is 0.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Suzhou Novoprotein Scientific Co. Ltd. A (688137)?
The net margin of Suzhou Novoprotein Scientific Co. Ltd. A is −54.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Suzhou Novoprotein Scientific Co. Ltd. A (688137)?
The return on equity (ROE) of Suzhou Novoprotein Scientific Co. Ltd. A is −4.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Suzhou Novoprotein Scientific Co. Ltd. A (688137)?
On an EBIT basis the return on assets of Suzhou Novoprotein Scientific Co. Ltd. A is 7.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Suzhou Novoprotein Scientific Co. Ltd. A (688137)?
The operating margin of Suzhou Novoprotein Scientific Co. Ltd. A is −66.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Suzhou Novoprotein Scientific Co. Ltd. A (688137)?
Revenue at Suzhou Novoprotein Scientific Co. Ltd. A is growing +6.7% versus a year earlier (3y avg −17.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Suzhou Novoprotein Scientific Co. Ltd. A (688137)?
Earnings per share at Suzhou Novoprotein Scientific Co. Ltd. A are growing −86.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Suzhou Novoprotein Scientific Co. Ltd. A (688137) generate?
The free cash flow of Suzhou Novoprotein Scientific Co. Ltd. A is −92.2M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Suzhou Novoprotein Scientific Co. Ltd. A in the live analysis

One click puts Suzhou Novoprotein Scientific Co. Ltd. A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.